Stock AnalizGrifols SA GRFS
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Grifols SA (GRFS) is a healthcare company listed in the US with a market value of about $6.0B. In the twelve months to September 30, 2026 it had revenue of $8.4B and net income of $539M, a net margin of 6.4%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is value (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 11.0, a price to free cash flow of 8.2, 5-year revenue growth of 6% a year, a 5-year average ROIC of 8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 25% above the current price.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Checks not passed
- PEG below 1.5
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.4B | $8.3B | $7.5B | $7.3B | $6.5B | $5.6B | $6.6B | $5.7B | $5.1B | $5.2B | $4.3B |
| Net income | $539M | $443M | $163M | $47M | $197M | $214M | $759M | $702M | $683M | $795M | $575M |
| Free cash flow | $730M | $688M | $696M | -$6M | -$304M | $396M | $1.0B | $290M | $579M | $708M | $320M |
| EPS (diluted) | $0.79 | $0.65 | $0.24 | $0.07 | $0.29 | $0.31 | $1.10 | $1.02 | $0.99 | $1.16 | $0.84 |
| Net margin | 6.4% | 5.3% | 2.2% | 0.6% | 3.0% | 3.8% | 11.6% | 12.3% | 13.3% | 15.3% | 13.5% |
| ROIC | — | — | 11.0% | 6.4% | 5.9% | 4.9% | 9.4% | 10.5% | 8.7% | 11.0% | 18.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Grifols SA’s P/E ratio?
About 11.0, based on the last twelve months of diluted earnings per share (forward P/E about 7.1).
Is Grifols SA stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 25% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Grifols SA pay a dividend?
Yes. The dividend yield is about 1.20%, and it has paid dividends for 9 years in our data.
Is Grifols SA a good stock to buy?
We do not give buy or sell advice. Grifols SA scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.